SHANGHAI, Sept. 17, 2015 /PRNewswire/ -- ShangPharma announced its plans to establish a subsidiary in the Qidong Biopharma Industrial Zone as part of a multistage expansion project for its biologics service portfolio. In the first phase, Shangpharma and Qidong Biopharma Industiral zone will invest 60 million USD to build a comprehensive and multifunctional pre-clinical research facility as well as a state-of-the-art biologics manufacturing facility. The Preclinical facility will be operated by ShangPharma's CRO division, ChemPartner and the Biologics manufacturing facility will be operated by Shangpharma's CMO division, China Gateway Biologics. During the construction phase of the manufacturing facility, the company's existing biologics CMC facility will continue to operate out of its Shanghai site.
The new China Gateway Biologics' manufacturing facility will provide commercial scale operations for biopharmaceuticals. It will becomprised of one 500L single-use mammalian cell culture train for clinical phase supply and two 2000L trains for commercial manufacturing. These capabilities will be complemented with fill & finish capabilities of the appropriate scale.
Michael Hui, CEO of ShangPharma stated, "I am proud that Qidong Biopharma Industrial Zone has selected ShangPharma as partner for the first facility of this kind in Qidong. The investment offers China Gateway Biologics the opportunity to grow to the next level as a full biopharmaceutical service provider from preclinical development to commercial scale. We strongly believe the state-of-the-art single use facility conforming to Western standards will be able to support our international client base."
Xu Feng, Qidong's Party Secretary and Chairman of Qidong Standing Committee of the People's Congress said, "Choosing ShangPharma as the first tenant for the biopharma zone in Qidong is a big milestone to establish Qidong as a biotech hub at the door steps of Shanghai. ShangPharma/CGB is a strong partner with international focus and the facility will serve as model for other projects of similar scale and needs."
The biopharmaceutical manufacturing facility shall be operational for the first client project in early 2018.
ShangPharma is comprised of a family of companies including China Gateway Biologics, China Gateway Pharmaceutical Development, ChemPartner, ShangPharma Technology and ShangPharma Investment. The group is actively investing, licensing, and forming partnerships to better serve the healthcare industry. ShangPharma aims, through all its divisions, to create an ecosystem that allows close interaction between major hospitals and academic centers, by matching them with pharmas, biotech, and research institutes to enable the success of all.
About China Gateway Biologics
China Gateway Biologics is a full service provider of biologics manufacturing for the biopharmaceutical industry. It serves both Chinese domestic and international client base from preclinical to commercial scale in China with Western standards.
ChemPartner is a leading contract research organization providing high-quality and cost-effective services for the global pharmaceutical and biotechnology industry. The company offers a broad range of integrated services across the drug discovery and development process. ChemPartner's services consist of discovery biologics, discovery chemistry, discovery biology and preclinical development.